AVEO Pharma (AVEO) Misses Q4 EPS by 7c; Updates on Financial Outlook

AVEO Pharma (NASDAQ: AVEO) reported Q4 EPS of ($0.11), $0.07 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $100 thousand.

Updated Financial Guidance

AVEO believe that its cash resources would allow the Company to fund its current operations into the fourth quarter of 2017. This estimate does not include the payment of potential licensing milestones or the uncommitted costs of conducting any contemplated clinical trials, and assumes no milestone payments from AVEO’s partners, no additional funding from new partnership agreements, no equity financings, no debt financings or accelerated repayment thereof and no further sales of equity under the Company’s ATM. This estimate also does not include any amount AVEO may agree to pay in excess of the estimated settlement liability, for accounting purposes, that the Company has established with respect to a potential settlement of claims with the SEC, as described in the Company’s 2015 annual report filed on Form 10-K.

For earnings history and earnings-related data on AVEO Pharma (AVEO) click here.

You May Also Be Interested In

• Diana Shipping withdraws bid to acquire Genco Shipping
• bioAffinity Technologies closes $4M private placement offering
• Realty Income closes $1B convertible notes offering